Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06525350
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-18
Brief Title:
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and DocetaxelAlbumin BoundVerse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Controlled Open-label Phase Ⅱ Study to Evaluate the Safety Tolerability and Efficacy of the Combination of Glumetinib Tablets and Docetaxel for InjectionAlbumin BoundVerse Docetaxel in the Treatment of Locally AdvancedRecurrent or Distant Metastasized Non-small Cell Lung Cancer Patients With MET Overexpression
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study consists of Stage 1 including dose escalation and dose expansion and Stage 2 randomized controlled study The main purpose of Stage 1 is to preliminarily evaluate the safety and tolerability of the combination of glumetinib Tablets and Docetaxel for InjectionAlbumin BoundHB1801 in the treatment of MET-overexpressed non-small cell lung cancer NSCLC The main purpose of Stage 2 is to evaluate the efficacy of the combination of glumetinib tablets and HB1801 compared to glumetinib tablets monotherapy or docetaxel in the treatment of MET-expressed NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None